RT Journal
A1 Moss JM
T1 THe ugdp scandal and cover-up
JF JAMA
JO JAMA
YR 1975
FD May 26
VO 232
IS 8
SP 806
OP 808
DO 10.1001/jama.1975.03250080010002
UL http://dx.doi.org/10.1001/jama.1975.03250080010002
AB To the Editor.— 
    For almost five years, diabetic patients who can be safely treated with tolbutamide have been tormented by repeated headlines saying that they are being improperly and dangerously treated. Never has there been such a concerted effort to undermine the confidence of patients in their family physician. This confidence is essential for the successful treatment of any chronic disease.The original University Group Diabetes Program (UGDP) report was given to the press four weeks before it was presented to a scientific meeting where it could be adequately criticized. This report was given to the press seven months before it was published and could be adequately studied. The Food and Drug Administration endorsed the study before publication and over the objection of their own advisory committee for endocrine drugs. The witnesses who testified before Senator Nelson's committee last year were carefully selected to include only those who agreed with